HIV drugs may weaken bones: new study investigates

NCT ID NCT00146094

Terminated Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at bone density in HIV-positive men to see if antiretroviral drugs cause bone thinning. Researchers compared men starting HIV treatment with those not yet on therapy over two years. The goal was to understand why bone loss is more common in HIV patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antiretrovirals
What this could lead to: If successful, this study could clarify whether HIV drugs contribute to bone loss, guiding safer treatment strategies.
What could go wrong: This small, terminated study may not yield conclusive results. It only included Caucasian men, so findings may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic HIV infectious disease osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPENIA OSTEOPOROSIS

Contacts and locations

Locations

Centre Hospitalier de Colmar

Colmar, 68021, France
Centre Hospitalier de Mulhouse

Mulhouse, 68070, France
Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.